Mobile website
A Multi-Center Clinical Study of Anti-CD20 Monoclonal Antibody in Combination with CHOP Regimen for Treatment of Diffuse Large B Cell Lymphoma
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective: To evaluate the efficacy of rituximab combined with cyclophosphamide, vincristine, doxorubicin and prednisone (CHOP regimen) in treating the initially diagnosed diffuse large B cell lymphoma (DLBL). Methods: 2002-04-2003-02, 52 patients were enrolled in this study. Chemotherapy was conducted with cyclophosphamide 600 mg·m-2, vincristine 1.4 mg·m-2, docorubicin 25 mg·m-2 on d1 and prednisone 60 mg·d-1 for successive 5 d, every 3 weeks, for 6 courses. Rituximab was given at the dose of 375 mg·m-2 every 1 or 3 weeks, for 4 or 6 courses. Results: In 50 patients who were evaluated for efficacy, complete response rate and overall response rate were achieved at 60% and 100%, respectively. 50 patients were followed-up for 2～30 weeks (mean 8±5) and estimated progress free survival (PFS) rate of 16 weeks was 87%. The regimen could be well tolerated, and the major adverse reactions were infusion-related response (32%) and hematological toxicities (20%).Conclusion: Rituximab in combined with CHOP can be successfully applied to the therapy of initially diagnosed diffuse large B cell lymphoma, with adverse reactions.
Keywords:
Project Supported:
Clc Number:
